TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06294483

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum creatinine and Alb/create ratio
Description: To detct complication of disease on kidney

Intervention type: OTHER
Intervention: 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.
Description: Is criteria of diagnosis of SLE

Intervention type: OTHER
Intervention: 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.
Description: Is criteria of diagnosis of SLE

Intervention type: OTHER
Intervention: SLEDAI scores
Description: Is score to detect the activity of disease
Study: NCT05716217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm training
Description: Daily arm training program
Study: NCT05724485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Branched-chain Amino Acid
Description: 12.45 grams of BCAA orally per day before bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12.45 grams of Maltodextrin orally per day before bedtime
Study: NCT06294483

Intervention type: OTHER
Intervention: SLEDAI scores
Description: Is score to detect the activity of disease
Study: NCT06452927

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic enucleation of the prostate
Description: Endoscopic enucleation of the prostate, regardless of energy source.~Also see:~* Enucleation is enucleation is enucleation is enucleation~* PMID: 27585786 DOI: 10.1007/s00345-016-1922-3
Study: NCT05230615

Intervention type: DRUG
Intervention: Oral semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study: NCT04840524

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laminate veneers preparation
Description: facial laminate veneers teeth preparation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laminate veneers preparation
Description: facial laminate veneers teeth preparation
Study: NCT05277090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L of polyethyleneglycol
Description: 2L of polyethyleneglycol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L of polyethyleneglycol
Description: 2L of polyethyleneglycol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L of polyethyleneglycol
Description: 2L of polyethyleneglycol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inulin
Description: 15g inulin per day

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: probiotic combination product
Description: participants take 2L of polyethyleneglycol, subsequently take 15g probiotics combination product (including Bifidobacterium lactis, Lactobacillus plantarum, inlulin, Vitamin C) per day. The probiotic combination product, named Mei Ri Yi Jun was produced by Wedge Pharmaceuticals.
Study: NCT04974086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexually transmitted infection (STI) testing clinical decision support (CDS) tool
Description: The intervention, called the STI Testing CDS tool, includes integrating STI testing guideline prompts into the electronic health record (EHR). The prompt guides clinicians to assess and broadly respond to adolescents' sexual health behaviors through EHR survey data. Through the CDS tool, clinicians will be prompted to provide comprehensive and evidence-based sexual health care for teens including, for example: providing patient-facing education about sexual preventative health topics and facilitating ordering of HIV and sexually transmitted infection (STI) laboratory tests to improve both risk-based and routine annual preventative screening.
Study: NCT06099288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Video and Motivational Interviewing Intervention
Description: The intervention consists of three home-based visits, followed by phone calls during the last three months of the intervention. For each visit and phone call, participants will receive tailored print materials, and during the 6 months of the interventions, they will receive text messages 2x/week. The intervention will be delivered in English or Spanish by a bilingual Community Health Worker (CHW). The CHW will be hired to serve as MI counselors for the parents in the study, and will be in charge of delivering the MI in-home or telephone sessions. CHWs will be trained for 3 months, in Motivational Interviewing, study protocols, the use of video recordings, meal preparation, and cooking, and will undergo a MI certification process. During the sessions with the participants, the CHW will deliver semi-scripted MI sessions based on the scripts developed in the pilot study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Read Educate and Develop Youth (READY) Comparison
Description: The comparison group will receive an attention contact control intervention about school readiness promotion adapted from R.E.A.D.Y. (Read Educate and Develop Youth) designed by the Michigan Department of Education. The intervention consists of three home-based visits, followed by phone calls during the last three months of the intervention. For each visit and phone call, participants will receive tailored print materials, and during the 6 months of the interventions, they will receive text messages 2x/week. The intervention will be delivered in English or Spanish by a bilingual Community Health Worker (CHW). Families will receive the same intervention components as the intervention, but about reading instead of nutrition.
Study: NCT06089486

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ICA
Description: Patients will undergo annual CAV surveillance with ICA

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET
Description: Patients will undergo annual CAV surveillance with PET
Study: NCT05662683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Description: Virtual reality glasses to be used in the research are not a medical device. This device is a technological glasses that works with compatible smartphones. During the PAP-SMEAR application to be made with this device, watching a nature video with VR is within the framework of midwifery care applications and is not a treatment option for any treatment method, agent or disease. Although the video watched with VR has no effect on medical treatment and care within the framework of midwifery care, it does not have any harmful effects on women. The participant can withdraw from this study at any time without giving any reason.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distraction Cards Practice Group
Description: It will take about 3-5 minutes to show the cards. The selection of the cards to be used is based on the cards suggested in the literature.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) Breathing Exercise Group
Description: From the preparation stage of the PAP-SMEAR ALDIRAN procedure to the completion of the application process that takes PAP-SMEAR, the virtual reality glasses for breathing exercise by clicking the youtube.com link (https://www.youtube.com/watch?v=Pddb09FAs68) after providing an internet connection with a smartphone for the image. will be provided.
Study: NCT06299956

Intervention type: OTHER
Group type: OTHER
Intervention: Supervised exercise therapy
Description: Walking on a treadmill at increasing elevation and pace.
Study: NCT05171361

Intervention type: PROCEDURE
Intervention: Pancreaticogastrostomy versus Pancreaticojejunostomy with Dunking Technique
Description: To compare between the outcomes of pancreaticogastrostomy and pancreaticojejunostomy with dunking technique after Pancreaticodudenectomy

Intervention type: PROCEDURE
Intervention: Pancreaticogastrostomy versus Pancreaticojejunostomy with Dunking Technique
Description: To compare between the outcomes of pancreaticogastrostomy and pancreaticojejunostomy with dunking technique after Pancreaticodudenectomy
Study: NCT04627441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulator
Description: DS8R Electrical Stimulator For Human Research

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural spinal cord stimulator system
Description: Spectra WaveWriter Epidural Spinal Cord Stimulator System with CoverEdge 32 Electrode Surgical Lead
Study: NCT04827186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spleen Transplantation/Removal
Description: Spleen transplantation/removal and kidney transplantation alone or simultaneous kidney and pancreas transplantation in highly sensitized patients with either a positive flow cytometry cross-match (FCXM) (T or B cell positive) or a complement-dependent cytotoxicity (CDC) cross-match (B cell positive).
Study: NCT05463835

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RubusElite
Description: Each 500ml serving of this beverage will contain approximately 30g of milk protein alongside 750mg of polyphenols derived from blackberry puree. The study participant will consume 2 x 500ml per day which will contribute 60g protein and 1500mg polyphenols. No adverse effects associated with the consumption of dairy protein or berry fruits at the proposed intake levels have been reported to date.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 'Protein rich' dairy beverage
Description: This dairy beverage will contain approximately 30g of milk protein /500ml serving and will not contain polyphenols.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: 'Low Protein' dairy beverage
Description: This product also contains no polyphenols and negligible protein.
Study: NCT05694936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Description: Sodium valproate oral continuously in a twice daily dose (Initial dose of 600mg/d up-titrated to target daily dose of 20 mg/kg/d at Cycle 1 Day 13, then dose adjusted to maintain serum VPA levels within the target range of 50-100 μg/mL); Refer to arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
Study: NCT05240547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: Spinal manipulative therapy delivered to the cervical spine by a chiropractor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham manipulative treatment delivered to the cervical spine by a chiropractor
Study: NCT05168514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Patient Identification Form, Pittsburgh Sleep Quality Index and McGill Pain Scale Short Form will be applied to patients with written and verbal consent. Scales and massage application will be done before the pharmacological agent is administered to the patients.~Back massage will be applied to the experimental group for 10 minutes every day for 10 days. Routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the experimental group before and after each massage and scores will be recorded for 10 days.~The control group will not be interfered with, and the routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the control group simultaneously with the experimental group and scores will be recorded for 10 days.
Study: NCT06329271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early-Weight bearing
Description: The patients began early weight bearing under attending physician and physiotherapist surveillance within 48 hours after surgery. Patients were instructed to stand up near the bed, and muscle power, gait stability, and pain tolerance were recorded. The physiotherapist instructed the patients to perform early mobilization and weight bearing as tolerable by self-adjustment of body weight distribution over the bilateral lower extremities, and walking assistance was used to prevent repeat falling accidents.
Study: NCT06406868

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: American Cancer Society
Description: After taking base line readings the patients will be divided into two groups' experimental group and control group by randomization. The experimental group will receive tele rehabilitation and the control group will receive outpatient rehabilitation. Readings will be taken at the end of every week. The treatment plan of both groups will be the same according to the exercise plan given by American Cancer Society guidelines for breast cancer patients. The exercise plan will start on third day of surgery. A pictorial reference will be given to every patient to perform exercise.~The exercise session will be thrice a week, for 60 min, and for four consecutive weeks, for 12 sessions. Exercise plan consists of three phases:~warm up, balance exercise ,cool down

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: American Cancer Society
Description: After taking base line readings the patients will be divided into two groups' experimental group and control group by randomization. The experimental group will receive tele rehabilitation and the control group will receive outpatient rehabilitation. Readings will be taken at the end of every week. The treatment plan of both groups will be the same according to the exercise plan given by American Cancer Society guidelines for breast cancer patients. The exercise plan will start on third day of surgery. A pictorial reference will be given to every patient to perform exercise.~The exercise session will be thrice a week, for 60 min, and for four consecutive weeks, for 12 sessions. Exercise plan consists of three phases:~warm up, balance exercise ,cool down
Study: NCT05241054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: With patient in supine position, the patient will be placed on the operating table with a head-up tilt to reduce venous congestion at the operative site. Skin will be disinfected, the patient will receive local anesthesia by paranasal infiltration at the incision site with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerine
Description: This group includes 32 patients (anticipated), infusion of Nitroglycerine (TNG) (0.2-1µg/kg/min) will be started and adjusted to maintain mean arterial blood pressure between 55-65mmHg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General anesthesia will be induced using IV propofol at dose of 1-2 mg.kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General anesthesia will be induced using IV propofol at dose of 1-2 mg.kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl 1 microgram.kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl 1 microgram.kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium Besylate
Description: Atracurium besylate 0.5mg.kg to facilitate intubation followed will top up dose of atracurium(0.1mg/kg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium Besylate
Description: Atracurium besylate 0.5mg.kg to facilitate intubation followed will top up dose of atracurium(0.1mg/kg).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation
Description: Patient will then be mechanically ventilated using a volume control mode with tidal volume 6-8ml/kg, respiratory rate 10-14 breath/min and I.E ratio1:2 to maintain end tidal CO2 around 35 mmHg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation
Description: Patient will then be mechanically ventilated using a volume control mode with tidal volume 6-8ml/kg, respiratory rate 10-14 breath/min and I.E ratio1:2 to maintain end tidal CO2 around 35 mmHg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia will then be maintained using sevoflurane 2%, and 60% air in oxygen mixture and top up dose of

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia will then be maintained using sevoflurane 2%, and 60% air in oxygen mixture and top up dose of
Study: NCT04800614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitravatinib
Description: 100 mg sitravatinib on Day 1 of each of 3 periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitravatinib
Description: 100 mg sitravatinib on Day 1 of each of 3 periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitravatinib
Description: 100 mg sitravatinib on Day 1 of each of 3 periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitravatinib
Description: 100 mg sitravatinib on Day 1 of each of 3 periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitravatinib
Description: 100 mg sitravatinib on Day 1 of each of 3 periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitravatinib
Description: 100 mg sitravatinib on Day 1 of each of 3 periods
Study: NCT06098144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm C-Q Gum
Description: Participants will receive a 6-week supply of nicotine replacement treatment (NRT). Based on participants' self-report on the number of cigarettes smoked, these are the possible dosages of NRT gum (2 mg and 4 mg). Participants should not smoke and use the nicotine gum at the same time. Nicotine gum should only be used when cravings for cigarettes arise and should not be treated like regular chewing gum. It is not to be constantly chewed~NRT will be distributed based on the treatment condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm C-Q Gum
Description: Participants will receive a 6-week supply of nicotine replacement treatment (NRT). Based on participants' self-report on the number of cigarettes smoked, these are the possible dosages of NRT gum (2 mg and 4 mg). Participants should not smoke and use the nicotine gum at the same time. Nicotine gum should only be used when cravings for cigarettes arise and should not be treated like regular chewing gum. It is not to be constantly chewed~NRT will be distributed based on the treatment condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Quit-line
Description: The TQL is free, and the TQL counselor will provide three phone counseling sessions lasting approximately 15 minutes to devise a specific plan to quit smoking and arrange the delivery of 4 to 12 weeks of NRT based on need. Participants will be advised to request nicotine gums instead of patches to accommodate their job circumstances.
Study: NCT05241054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringers
Description: Intravenous infusion of Lactated Ringers will be given per body weight and according to intraoperative loss

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringers
Description: Intravenous infusion of Lactated Ringers will be given per body weight and according to intraoperative loss

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Head-up tilt
Description: The patient is placed on the operating table with a head-up tilt to reduce venous congestion at the operative site
Study: NCT06098144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Quit-line
Description: The TQL is free, and the TQL counselor will provide three phone counseling sessions lasting approximately 15 minutes to devise a specific plan to quit smoking and arrange the delivery of 4 to 12 weeks of NRT based on need. Participants will be advised to request nicotine gums instead of patches to accommodate their job circumstances.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Counseling
Description: The counseling session will discuss preparing to quit, coping with job-related stress, getting social support, the 5A's for preventing relapse (Avoid, Alter, Alternatives, Anticipate, and Active), proper use of NRT, and last approximately 30 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Behavioral Counseling
Description: Participants will receive four weekly counseling sessions which include information about how to quit, challenges, and short and long-term relapse prevention. Each session will last approximately 20 minutes.
Study: NCT04935008

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The recruitment maneuver
Description: In patients with ARDS, 30 cm H2O positive pressure support and 30 seconds recruitment maneuver will be applied. The effect of the recruitment maneuver on intracranial pressure will be investigated by measuring the optic nerve sheath diameter with the help of ultrasonography before and after the recruitment maneuver. Optic nerve diameter will be evaluated with a linear probe on the eyeball before and after the collection maneuver, taking a value of 3 mm from the eyeball.
Study: NCT05241054

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Head-up tilt
Description: The patient is placed on the operating table with a head-up tilt to reduce venous congestion at the operative site

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: paracetamol infusion (15 mg/kg) will be given by IV infusion in both groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: paracetamol infusion (15 mg/kg) will be given by IV infusion in both groups
Study: NCT05829135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acuvue Oasys with Transitions
Description: soft contact lenses with darkening technology
Study: NCT00938990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam